"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial of 67Cu-C595 for invasive bladder cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was looking at a treatment called 67Cu-C595 for invasive bladder cancer. This trial was supported by Cancer Research UK.
Bladder cancer is often treated with surgery. Other treatments are sometimes used as well, to help stop the cancer coming back. 67Cu-C595 is a radioactive molecule (67Cu) that is linked to a monoclonal antibody (C595).
Monoclonal antibodies can target particular types of cells and attack them. The monoclonal antibody in this trial had been designed to target bladder cancer cells. The aim of this trial was to use the monoclonal antibody to deliver the radiation directly to the bladder cancer cells. The doctors hoped that 67Cu-C595 would be effective in treating bladder cancer, and help stop the cancer coming back.
This was a phase 1 trial of an experimental treatment. The aim of the trial was to see what dose of 67Cu-C595 was the most effective without causing serious side effects.
Summary of results
This trial was never finished so there are no results available. The researchers were unable to recruit enough patients.
How to join a clinical trial
Mr M Bishop
Cancer Research UK (Centre for Drug Development)
Clatterbridge Cancer Centre NHS Foundation Trust
This is Cancer Research UK trial number CRUKD/01/020.